

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**EVEREST MEDICINES**

**云 頂 新 耀**

**Everest Medicines Limited**

**雲 頂 新 耀 有 限 公 司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1952)**

## **POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON TUESDAY, 1 JUNE 2021**

Reference is made to the circular (the “**Circular**”) of Everest Medicines Limited (the “**Company**”) incorporating, amongst others, the notice (the “**Notice**”) of the annual general meeting of the Company (the “**AGM**”) dated 30 April 2021. Unless the context requires otherwise, the capitalized terms used herein shall have the same meanings as those defined in the Circular.

At the AGM held on 1 June 2021, all the proposed resolutions as set out in the Notice were taken by poll. The poll results in respect of the resolutions proposed at the AGM are as follows:

<b>Ordinary Resolutions</b>		<b>Number of Votes (%)</b>	
		<b>For</b>	<b>Against</b>
1.	To receive and adopt the audited consolidated financial statements of the Company for the year ended 31 December 2020 and the reports of the Directors and the independent auditor thereon.	261,878,748 (100.000000%)	0 (0.000000%)
2(a).	To re-elect Mr. Wei Fu as an executive Director.	259,273,050 (99.004998%)	2,605,698 (0.995002%)
2(b).	To re-elect Mr. Ian Ying Woo as an executive Director.	261,123,224 (99.711499%)	755,524 (0.288501%)
2(c).	To re-elect Mr. Xiaofan Zhang as an executive Director.	261,123,224 (99.711499%)	755,524 (0.288501%)
2(d).	To re-elect Ms. Lan Kang as a non-executive Director.	260,973,971 (99.654505%)	904,777 (0.345495%)
2(e).	To authorize the board of directors (the “ <b>Board</b> ”) to fix the remuneration of the Directors.	261,878,748 (100.000000%)	0 (0.000000%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
3.	To re-appoint PricewaterhouseCoopers as the auditor and to authorize the Board to fix their remuneration.	261,878,748 (100.000000%)	0 (0.000000%)
4.	To grant a general mandate to the directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of passing of this resolution.	261,878,748 (100.000000%)	0 (0.000000%)
5.	To grant a general mandate to the directors to issue, allot and deal with additional shares in the capital of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	237,112,438 (90.542833%)	24,766,310 (9.457167%)
6.	To extend the general mandate granted to the directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares repurchased by the Company.	236,945,438 (90.479063%)	24,933,310 (9.520937%)

*Notes:*

- (a) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 6, all resolutions were duly passed as ordinary resolutions.
- (b) As at the date of the AGM, the total number of shares of the Company in issue was 296,847,861 Shares, being the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM. The full text of the aforesaid resolutions was set out in the Circular.
- (c) There were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).
- (d) No shareholder of the Company was required under the Listing Rules to abstain from voting on the resolutions at the AGM.
- (e) None of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.
- (f) The Company’s Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

By order of the Board  
**Everest Medicines Limited**  
**Wei Fu**  
*Chairman and Executive Director*

Hong Kong, 1 June 2021

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.*